Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05231122
Title Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.